U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06906016) titled 'New HBV Infection Biomarkers: Clinical Characterization and Impact on Management' on March 04.
Brief Summary: Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In France, it affects around 0.3% of the population. Current clinical practice relies on traditional biomarkers, such as HBV DNA and HBsAg, to monitor viral replication and disease progression. However, these biomarkers do not fully capture the viral activity or predict clinical outcomes. Recently, new biomarkers like HBcrAg and HBV RNA have emerged, sh...